In this review, the authors summarize possible mechanisms by which infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, may cause AD in elderly COVID-19 patients and describe preventive measures to mitigate risk.
The European Federation of Neurological Associations, in partnership with the NeuroCOVID-19 taskforce of the European Academy of Neurology, has investigated the impact of the first wave of the COVID-19 pandemic on patients with neurological diseases, as well as the hopes and fears of these patients about the post-pandemic phase.
The aims of this study were to analyze the characteristics and outcomes of patients with stroke admitted during the second COVID-19 wave and to evaluate the differences in the stroke care provision compared with the first wave.
In this article the authors investigated induction of antigen-specific antibody, B cell and T cell responses longitudinally in patients with multiple sclerosis (MS) on anti-CD20 antibody monotherapy (n = 20) compared with healthy controls (n = 10) after BNT162b2 or mRNA-1273 mRNA vaccination.
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an unprecedented global health crisis. However, therapeutic options for treatment are still very limited.
The objective of this study was to derive and validate risk prediction algorithms to estimate the risk of COVID-19 related mortality and hospital admission in UK adults after one or two doses of COVID-19 vaccination.